Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
NCI seeks bioengineering innovation to enhance solutions for cancer research and care in exploratory/developmental grants.
Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | and similar dates through November 2027
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; max project period 2 years.
Summary: Supports exploratory/developmental bioengineering research to demonstrate feasibility and potential utility of new or improved solutions for biomedical, pre-clinical, or clinical research and care; clinical trials are not allowed.
Key Information: Limited submission: each application must be scientifically distinct; foreign organizations are eligible; clinical trials are not permitted.
Description
This opportunity, offered by the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR) under the NIH, supports exploratory and developmental bioengineering research projects (R21 mechanism) that aim to demonstrate the feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, cost, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. The program is designed to catalyze innovative, multidisciplinary approaches that bridge engineering and biomedical sciences, with a focus on early-stage development and feasibility testing.
Projects may include, but are not limited to:
- Assessing the feasibility of novel tools for clinical intervention
- Exploring new approaches to modeling complex biological systems
- Improving or integrating existing technologies to address unsolved biomedical problems
- Establishing preliminary evidence for transformative bioengineering approaches
Applications must not propose clinical trials.
